Figure 1. Schema of study treatment and acquisition of correlative samples. Patients started a 2-wk run-in of single-agent hydroxychloroquine (HCQ), which they continued during 3 wk cycles of standard bortezomib (B) on d 1, 4, 8, and 11. Solid arrows indicate time points at which samples were obtained for all patients; this included peripheral blood mononuclear cells obtained at baseline, on d 1 and 8 of cycle 1, and on d 1 of cycle 2, as well as bone marrow samples obtained at baseline and on d 1 of cycle 1. The hatched arrows indicate that the bone marrow samples obtained on combined HCQ and bortezomib were either on d 5 of cycle 1 (the final 3 patients) or d 1 of cycle 2 (all previous patients).